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116 Poster Session-IIPatients with cGVHD had significantly higher BAFF:B cell ratios
and fewer circulating IgD1CD38LoCD27- (naive) and
IgD1CD38HiCD27- (transitional) B cells compared to patients
without cGVHD. All HSCT patient groups had elevated BAFF
levels but patients without cGVHDhad supranormal numbers of na-
ive and transitional B cells resulting in normal BAFF:B cell ratios.
This suggests that increased numbers of naive B cells in patients
without cGVHD reflect a normal B cell homeostatic compensatory
mechanism. Patients with cGVHDhad fewer B cells, but unlike nor-
mal CD271 antigen-experienced B cells, CD271 B cells from
cGVHD patients were in vivo activated and capable of IgG produc-
tion without additional antigen or second signal stimulation. Serial
measurements of BAFF and B cell subsets in a second series of 25 pa-
tients followed for 1 year post-HSCT revealed high BAFF levels as-
sociated with B cell lymphopenia in all patients early post-HSCT.
Following autologous HSCT (n5 8) BAFF levels decreased rapidly
as B cell numbers recovered after transplant. In patients without
cGVHD (n5 8), BAFF levels also decreased as peripheral B cells re-
constituted. In contrast, patients who developed cGVHD (n 5 17)
had persistently elevated BAFF levels. In these patients, elevated
BAFF levels were associated with delayed reconstitution of naive B
cells and proportional increases in antigen-experienced CD271 B
cells in the first year post-HSCT.These studies demonstrate distinct
abnormalities in B cell homeostasis associated with excess BAFF in
patients with cGVHD and begin to delineate mechanisms of B cell
pathophysiology in these patients. BAFF appears to play a critical
role in the maintenance of functionally activated B cells after
HSCT and BAFF targeting agents may be useful in the treatment
of cGVHD.323
FEMALE DONOR H-Y SEROPOSITIVITY DOES NOT PREDICT MALE RECIP-
IENT HCT OUTCOMES, INCLUDING CGVHD
Sahaf, B.1, Narasimhan, B.2, Miller, K.1, Spencer, K.1, Spellman, S.3,
Miklos, D.1 1Stanford University, Stanford, CA; 2Stanford, CA; 3Na-
tional Marrow Donor Program, Minneapolis, MN
Following HLA-identical hematopoietic cell transplantation
(HCT), T and B cells target minor histocompatibility antigens
(mHA) providing beneficial GVL and detrimental GVHD. Males
who have undergone sex-mismatched allogeneic HCT (F/M) ex-
perience more GVHD and less disease relapse compared to any
other donor and recipient gender combination. Y chromosome en-
coded mHA, H-Y antigens, are frequently recognized by T and B
cells following F/MHCT. Earlier, we developed ELISA for 5 H-
Y antigens (DDX3Y, UTY, RPS4Y1, ZFY, and EIF1AY), and
showed 50% of F/M HCT patients develop specific antibodies
for any of these H-Y antigens 4–12 months after HCT. H-Y anti-
body develops in association with cGVHD and persistent disease
remission (p\0.0001). In addition, 30% of females have low-titer
H-Y antibodies, while males have no antibodies. Here, we study
whether preexisting H-Y antibodies in female donors predict
male recipient cGVHD or relapse and overall survival. In collabo-
ration with the NMDP and CIBMTR, pretransplant sera were col-
lected from 289 female donors who donated unrelated bone
marrow for HLA-identical male recipients undergoing myeloabla-
tive HCT for AML(18%), CML(38%), ALL(24%), MDS(13%),
and NHL(7%). Primary immune prophylaxis was CSA/ FK506
plus MTX (78%) and T Cell depletion (22%). With eight year me-
dian follow-up, cGVHD incidence was 47%, 18% relapsed, and
overall survival was 50.2% at one year and 41.8% at two years.
22.3% female donor sera tested positive for any H-Y antigen by
ELISA. To test for alternative antigen presentation chemistry,
H-Y antigens were also printed onto nitrocellulose microarrays at
0.1 mg/ml, incubated with sera and H-Y specific antibody was de-
tected with anti hIgG. H-Y microarrays detected antibodies for
any H-Y antigen in 33% of female donors. H-Y seropositivity
did not correlate with donor age by quartile. H-Y seropositivity
did not correlate with the reported number of donor pregnancies:
nulliparous (38%), one (16%), two (19%), and three or more
(26%). Male recipients of H-Y seropositive donors had 51.2%
cGVHD incidence, 20.1% relapse, and 45.8% overall survival at
2 years. By Cox regression analysis, these clinical outcomes for
seronegative donors did not differ significantly: 42.7% cGVHD,
17.8% relapse, and 39.3% overall survival. Testing for H-Yantibodies in female donors before sex-mismatched HCT will not
predict cGVHD or relapse risk suggesting cGVHD and GVL
responses develop from naı¨ve and not memory lymphocytes.324
NOVEL VACCINATION STRATEGY TO REDUCE ALLOANTIGEN SPECIFIC
RESPONSES
Toubai, T.1, Malter, C.T.1, Tawara, I.2, Sun, Y.1, Lowler, K.P.2,
Ferrara, J.L.M.2, Reddy, P.1 1University of Michigan, Ann Arbor, MI;
2University of Michigan, Ann Arbor, MI
Vaccinations are generally performed to enhance alloantigen spe-
cific immune responses. However, whether it can be utilized to
dampen alloantigen specific immune responses is not known. There-
fore, we tested the hypothesis that vaccination of donors with host-
derived CD8a1 dendritic cells (DCs), which are known to be tolero-
genic, will reduce host-specific donor T cell responses. We vacci-
nated donor (BALB/c) mice with host (B6) bone marrow (BM)
derived CD8a1DCs. Both unvaccinated donors and those vacci-
nated with CD8a- DCs served as controls. BM derived DCs were
sorted for CD11c1CD8a1 or CD11c1CD8a- DCs. CD8a1 and
CD8a- DCs were injected into donors and T cells were harvested.
BALB/c T cells from the B6 CD8a1DC vaccinated mice (hereafter
referred to as CD8a1DC Tvac) demonstrated significantly reduced
proliferation, secretion of IL-2 and IFN-g but greater secretion of
IL-10 in an MLR with B6 DCs when compared with T cells from
non-vaccinated and CD8a- DCs vaccinated mice. By contrast they
demonstrated equivalent proliferation when stimulated with DCs
from a third party (C3HHEJ) demonstrating loss of only antigen
specific responses. The reduction in allo-antigen responses by the
CD8a1DC Tvac cells was also not apparent with T cells from
IL-10 deficient donors, demonstrating a functional relevance for
IL-10. We next evaluated the impact of CD8a1DC Tvac cells in
a clinically relevant model of GVHD. Recipient (B6) mice were le-
thally irradiated and transplanted on day 0 with TCD BM from syn-
geneic (B6) or allogeneic (BALB/c) donors along with 4 106 T cells
from either unvaccinated or B6 BM CD8a1 DC or CD8-DC Tvac
cells from allogeneic (BALB/c) donors. Recipients of CD8a1 DC
Tvac demonstrated significantly better survival (70% vs 0%,
p\0.001) and reduced clinical and histopathological severity of
GVHD when compared with the allogeneic controls. Post-BMT
analyses demonstrated, consistent in vitro, significantly less donor
T cell proliferation, higher serum levels of IL-10 and reduced levels
of TNF-a and IFN-g when compared with the allogeneic controls.
By contrast vaccination of IL-10KO (B6) with BALB/cCD8a1DCs
did not reduce GVHD after B6/BALB/c BMT demonstrating
a critical role for IL-10 in CD8a1DC vaccination mediated protec-
tion. In conclusion, host CD8a1DC vaccination of donors reduces
allo-antigen specific responses in vitro and GVHD severity in vivo.
Thus, vaccination strategies might be employed to reduce undesired
immune responses.325
IMPACT OF CYCLOSPORINE A (CSA) CONCENTRATION ON THE INCI-
DENCE OF SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT)
Mallard, F., Brissot, E., Chevallier, P., Guillaume, T., Delaunay, J.,
Ayari, S., Saulquin, B., Moreau, P., Harousseau, J.L., Mohty, M.
CHU de Nantes, Nantes, France
Previous studies have demonstrated that the immunosuppressive
effects of CsA (eg. inhibition of calcineurine in lymphocytes) may
be correlated with CsA blood concentration, especially in the con-
text of solid organ transplantation. This report investigated the
impact of CsA concentrations in the early post allo-SCT period,
on the incidence of severe acute GVHD, in 85 consecutive pa-
tients treated in a single centre between Jan. 2006 and Jan.
2008, and for whom CsA concentrations in the blood were mon-
itored weekly. 85 patients received CsA (usually at 3 mg/Kg/d, 2
or 3 d. prior to graft infusion) as a 24-h continuous infusion until
hematopoietic recovery and switch to oral formulation. Dose
modifications of CsA were performed to maintain adequate
trough blood levels and to prevent nephrotoxicity. Median age
P-value
Poster Session-II 117was 51 (range, 18–67) y., with 46 (54%) female donors, 33 (39%)
myeloid malignancies, 49 (58%) lymphoid malignancies, and 3
cases of SAA. The stem cell source was PBSC in 66 (78%) pa-
tients, while BM was used in 19 (22%) patients. 37 (43.5%)
were transplanted from a matched related donor, and 48
(56.5%) from a matched unrelated donor. A myeloablative condi-
tioning regimen was used in 24 (28%) patients, and 61 (72%) re-
ceived a reduced intensity regimen. The median concentrations of
CsA in the blood at 1, 2, 3 and 4 weeks after allo-SCT were 348
(range, 172–733), 284 (range, 137–535), 274 (range, 107–649), and
247 (37–695) ng/mL respectively. All patients engrafted at a me-
dian of 17 (range, 0–42) days after allo-SCT. With a median fol-
low-up of 16 (range, 5–29) months, grade 2–4 acute GVHD
occurred in 36 patients (42%) at a median of 29 (range, 6–100)
days after allo-SCT. The incidence of severe grade 3–4 acute
GVHD was 23% (95%CI, 14–32%). In multivariate analysis, we
found that higher whole-blood CsA concentration in the first
week following graft infusion, and before onset of acute GVHD
was the strongest parameter significantly associated with a reduced
the risk of severe grade 3–4 acute GVHD (P 5 0.01; RR 5 0.24;
95%CI, 0.08–0.73). This data indicates a close relationship be-
tween CsA trough blood concentration during the early post
allo-SCT period and the severity of acute GVHD. Inadequate
or insufficient early exposures to CsA can be a serious risk for de-
veloping severe acute GVHD. Therefore, precise monitoring of
CsA concentrations and achievement of a high CsA target concen-
tration may be an effective tool to prevent the onset of severe
acute GVHD.326
INFERIOR OUTCOME WITH ADDITION OF RITUXIMAB FOR ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN ACUTE LYM-
PHOBLASTIC LEUKEMIA (ALL)
Kebriaei, P.1, Munsell, M.2, Gutierrez, K.1, de Lima, M.1, Giralt, S.1,
Hosing, C.1, Popat, U.1, Qazilbash, M.H.1, Thomas, D.3,
Kantarjian, H.3, Khouri, I.F.1, Champlin, R.E.1 1University of Texas
M.D. Anderson Cancer Center, Houston, TX; 2University of Texas
M.D. Anderson Cancer Center, Houston, TX; 3University of Texas
M.D. Anderson Cancer Center, Houston, TX
We previously reported that rituximab was associated with a re-
duced incidence of acute graft versus host disease (GVHD) when in-
corporated into a standard transplant preparative regimen for ALL.
To confirm our findings, we conducted a randomized, prospective
study.
Methods: Adult ALL pts received a standard myeloablative con-
ditioning regimen of total body irradiation (TBI, 12 Gy in four daily
fractions) followed by etoposide 60 mg/kg  1 dose with allogeneic
HSCT. Rituximab was administered at 375 mg/m2 on days27,21,
17 and 114 following stem cell infusion in pts randomized to re-
ceive the drug. GVHD prophylaxis consisted of tacrolimus and
mini-dose methotrexate for all pts, and anti-thymocyte-globulin
was added to matched unrelated pts. Palifermin to reduce the inci-
dence of mucositis was administered to all pts. The first 20 pts
were randomized equally to the possibility of receiving rituximab,
with subsequent randomization based on a Bayesian adaptive algo-
rithm.
Results: Twenty-one pts have been entered onto study. Patient
characteristics and treatment outcomes are detailed in Table 1. Of
note, there were greater numbers of pts with disease beyond CR1
in the rituximab group. There was no significant difference between
the 2 treatment groups with respect to the incidence of acute
GVHD; 3 pts in the rituximab group developed chronic extensive
GVHD. Seven of 10 (70%) pts on the rituximab treatment arm
have died with a median time to death of 6.9 months: relapse n 5
4, infection n 5 2, organ failure n 5 1; no pts on the standard treat-
ment arm have died with a median follow-up of 14 months (range
3–32 months). Overall survival for the rituximab group was signifi-
cantly worse at 30% versus 100% for the standard treatment arm,
p 5 0.005. Four of 10 (40%) pts on the rituximab treatment arm
have had progressive disease, and all 4 of these pts died. Only 1 of
11 (9%) pts on the standard treatment arm had progressive disease
at 14.5 months after HSCT and remains alive at 17.6 months after
HSCT. In conclusion, our results demonstrate that the addition ofrituximab to the standard etoposide and TBI conditioning regimen
for allogeneicHSCT in ALL does not impactGVHD. Furthermore,
rituximab appears to negatively impact survival, with increased risk
of disease relapse. However, the small sample size and greater num-
bers of pts with advanced disease in the rituximab arm limit these
conclusions.
Table 1. Patient Characteristics and Treatment Results
Etoposide/ Etoposide/
TBI TBI/RituximabNo. pts No. ptsTotal Treated 11 10
Median Recipient
Age in Years (range)33 (20247) 32 (19252) 0.382Gender (%): 0.999
Female 3 (27) 3 (30)
Male 8 (73) 7 (70)
Diagnosis Status (%) 0.158
CR1 7 (64) 3 (30)
CR2 4 (36) 3 (30)
Beyond CR2 0 (0) 1 (10)
Relapse 0 (0) 3 (30)
Histology (%): 0.035
T-cell 0 (0) 4 (40)
B-cell 11 (100) 6 (60)
Ph1 (%) 0.311
No 7 (64) 9 (90)
Yes 4 (36) 1 (10)
Donor Type (%) 0.387
Matched related 6 (55) 3 (30)
Matched unrelated 5 (45) 7 (70)
Stem Cell Source (%)* 0.008
Bone marrow 3 (27) 9 (90)
Peripheral blood 8 (73) 1 (10)
Acute GVHD (%) 0.999
Grades II-IV 3 (27) 9 (90)
Grades III-IV 0 0
Chronic Extensive GVHD (%) 0 3 (33) 0.090
Overall Survival 100% 30% 0.005
Progression-Free Survival 90% 60% 0.009327
DEFECTIVE IMMUNE SYNAPSE FORMATION OF UMBILICAL CORD
BLOOD-DERIVED NATURAL KILLER CELL S IS ABROGATED BY
EX VIVO EXPANSION
Xing, D.1, Ramsay, A.G.2, Gribben, J.G.2, Decker, W.K.1, Li, S.1,
Robinson, S.N.1, Yang, H.1, David, S.1, Hosing, C.M.1,
Elizabeth, S.J.1, Zweidler-McKay, P.A.1, Bollard, C.M.3 1Universityof
Texas MD Anderson Cancer Center, Houston, TX; 2 Institue of Cancer
Barts and the London School of Medicine, London, United Kingdom; 3Bay-
lor College of Medicine, Hosuton, TX
Activated natural killer (NK) cells derived from cord blood (CB)
have been reported to mediate a significant graft versus leukemia ef-
fect (GVL). However unmanipulated CB NK cells exhibit poor cy-
tolytic activity against tumor cells in vitro, thus limiting their
clinical application. We investigated the mechanism for the poor
cytolytic activity of CB NK cells and whether the defect can be
overcome with ex vivo expansion. NK cell killing of the tumor tar-
get cells is achieved by the formation of a mature immune synapse,
followed by secretion of lytic granules containing perforin and
granzymes.We hypothesized that CBNK cells exhibit low cytotox-
icity against leukemia blasts due to a defect in the formation of the
immune synapse. We have found reduced ability of CB NK cells to
form immune synapses with leukemia target cells contributing to
the decreased cytotoxicity of unmanipulated CB NK cells com-
pared to adult peripheral blood (APB) NK cells. F-actin polariza-
tion was observed in a mean of 12% (range 9–21%) of the CB
NK cell/tumor cell conjugates versus a mean of 85% (range 68–
87) of APB NK/tumor conjugates (p\ 0.001). This impairment
could then be reversed by ex vivo expansion of CB NK cells with
